BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models
BRD-810 是一种高选择性 MCL1 抑制剂，具有优化的体内清除率，在实体肿瘤和血液肿瘤模型中具有强大的疗效
期刊:Nature Cancer
影响因子:23.5
doi:10.1038/s43018-024-00814-0
Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange, Jennifer Roth, Doug
